A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Shanghai JMT-Bio Inc.
Shanghai JMT-Bio Inc.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
AstraZeneca
Hoffmann-La Roche
Fudan University
Lund University Hospital
National Health Research Institutes, Taiwan
Fudan University
Shanghai Jiao Tong University School of Medicine
Merck Sharp & Dohme LLC
Fudan University
Karolinska University Hospital
Prestige Biopharma Limited
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
The Netherlands Cancer Institute
Henan Cancer Hospital
UNICANCER
Jinling Hospital, China
Fudan University
Fudan University
Spanish Breast Cancer Research Group
Cancer Trials Ireland
NSABP Foundation Inc
Zhongda Hospital
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Tanvex BioPharma USA, Inc.
Fudan University
UNICANCER
UNICANCER
GBG Forschungs GmbH
Austrian Breast & Colorectal Cancer Study Group
NSABP Foundation Inc
Shanghai Zhongshan Hospital
Fudan University
Alliance for Clinical Trials in Oncology
RenJi Hospital
Shanghai Henlius Biotech
Fudan University
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
West German Study Group
West German Study Group
Peking University
National Taiwan University Hospital
ChineseAMS
Institute of Cancer Research, United Kingdom
Danish Breast Cancer Cooperative Group
Hoffmann-La Roche